Search results for "IMMUNOLOGY"

showing 10 items of 9651 documents

A T2* MRI Prospective Survey on Heart and Liver Iron In Thalassemia Major Patients Treated with Deferasirox Versus Deferiprone and Desferrioxamine In…

2010

Abstract Abstract 4267 Introduction: Most deaths in thalassemia major (TM) result from cardiac complications due to iron overload. In thalassaemia available three iron chelation regimes in monotherapy may achieve different changes in cardiac iron and function and liver iron. No data are available in literature about prospective comparisons on cardiac iron and function and liver iron in TM patients treated with deferasirox (DFX) versus deferiprone (DFP) and desferrioxamine (DFO) in monotherapy. Magnetic Resonance (MR) is the unique non invasive suitable technique to evaluated quantitatively this issue. The aim of this multi-centre study was to assess prospectively in the clinical practice th…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryThalassemiaImmunologyDeferasiroxMagnetic resonance imagingCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologySurgerychemistry.chemical_compoundchemistryInternal medicineMedicineLiver ironMultisliceSiderosisbusinessDeferiproneProspective surveymedicine.drug
researchProduct

AB0210 Quality of Life Indexes in Patients with Very Early Rheumatoid Arthritis (VERA): A Two Center Subgroup Analysis from The Adapthera Cohort: Tab…

2016

Background The significance of early diagnosis and early therapy initiation in patients with RA is tremendous. ADAPTHERA is a state wide rheumatology network based in Rhineland-Palatinate, Germany. ADAPTHERA aims to improve RA prognosis and quality of patients` life by reducing the time-to-RA-diagnosis. While there have been a lot of studies regarding quality of life in patients with established RA 1,2 , adequate data concerning very early rheumatoid arthritis (VERA) (disease duration Objectives To study quality of life in VERA patients and to investigate its associations with various RA associated clinical and laboratory parameters. Methods In a two center subgroup analysis from the ADAPTH…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryVisual analogue scaleImmunologySubgroup analysisGeneral Biochemistry Genetics and Molecular BiologyRheumatologyRheumatologyQuality of lifeInternal medicineErythrocyte sedimentation rateCohortmedicinePhysical therapyImmunology and AllergyRheumatoid factorFunctional abilitybusinessAnnals of the Rheumatic Diseases
researchProduct

Response-based chemotherapy and involved field radiation for intermediate stage Hodgkin disease. A GISL/NHLSG trial.

2006

Abstract Background. Most of the patients with advanced stage Hodgkin lymphoma can be cured with a standard course of six cycle of ABVD chemotherapy plus involved field (IF)radiotherapy. Patients with less advanced stage or with a more responsive disease could possibly achieve a cure with a shorter course of chemotherapy. In 1992, in the pre-PET era, the GISL addressed the issue of the proper number of chemotherapy cycles planning a response-oriented, ABVD-based study for intermediate-stage Hodgkin’s lymphoma patients. Patients and Methods. From January 1992 to December 2002, 218 patients younger than 70 were enrolled. Eligible patients had histologically confirmed and clinically staged Hod…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentImmunologyPhysical examinationCell BiologyHematologymedicine.diseaseBiochemistrySurgeryLymphomaRadiation therapyNodular sclerosisABVDErythrocyte sedimentation ratemedicineStage (cooking)businessProgressive diseasemedicine.drug
researchProduct

Human antiphospholipid antibodies induce TNFα in monocytes via Toll-like receptor 8

2009

The antiphospholipid syndrome (APS) is characterized by recurrent arterial and/or venous thromboses, pregnancy loss and the presence of antiphospholipid antibodies (aPL). One of the discussed mechanisms of this thrombotic activity in APS patients is attributed to TNFalpha secretion in monocytes after aPL stimulation. To investigate this mechanism in detail, we employed a monoclonal aPL and IgG fractions of APS patients for stimulation of human peripheral monocytes. Stimulation with this monoclonal aPL resulted in an increased expression and secretion of TNFalpha, caused by specific upregulation of TLR8 mRNA and protein expression levels. To confirm the specificity of this finding we could d…

medicine.medical_specialtymedicine.drug_classBlotting WesternImmunologyEnzyme-Linked Immunosorbent AssayStimulationCell SeparationBiologyMonoclonal antibodyPeripheral blood mononuclear cellMonocytesProinflammatory cytokineDownregulation and upregulationimmune system diseasesAntiphospholipid syndromeInternal medicinemedicineHumansImmunology and AllergyReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaAntibodies MonoclonalHematologyAntiphospholipid SyndromeFlow Cytometrymedicine.diseaseEndocrinologyToll-Like Receptor 8MonoclonalImmunologyAntibodies AntiphospholipidElectrophoresis Polyacrylamide GelTumor necrosis factor alphaImmunobiology
researchProduct

IL-1β-converting enzyme (caspase-1) in intestinal inflammation

2001

IL-1β-converting enzyme (ICE; caspase-1) is the intracellular protease that cleaves the precursors of IL-1β and IL-18 into active cytokines. In the present study, the effect of ICE deficiency was evaluated during experimental colitis in mice. In acute dextran sulfate sodium-induced colitis, ICE-deficient (ICE KO) mice exhibited a greater than 50% decrease of the clinical scores weight loss, diarrhea, rectal bleeding, and colon length, whereas daily treatment with IL-1 receptor antagonist revealed a modest reduction in colitis severity. To further characterize the function of ICE and its role in intestinal inflammation, chronic colitis was induced over a 30-day time period. During this chron…

medicine.medical_specialtymedicine.drug_classCaspase 1BiologyProinflammatory cytokineMiceAntigens CDInternal medicinemedicineAnimalsColitisMice KnockoutMultidisciplinaryCaspase 1Interleukin-18InterleukinBiological SciencesColitismedicine.diseaseReceptor antagonistEndocrinologyImmunologyInterleukin 18Inflammation MediatorsCell activationIntracellularInterleukin-1Proceedings of the National Academy of Sciences
researchProduct

Estrogen receptor agonists and immune system in ovariectomized mice.

2006

Several data implicate the immune system in bone lost after estrogen deficiency, however, some of the effects on the immune system of estrogen deficiency or of estrogen receptor (ER) modulation are not well established. In this study, the effect of ER agonists on the immune system in ovariectomized mice is analyzed. Mice were ovariectomized and were administered 17β-estradiol (E2), raloxifene (RAL) or genistein (GEN). The effect of a 4-week treatment on bone turnover and on several parameters that reflect the status of the immune system was studied. Results show that ovariectomy provoked both uterine atrophy and thymic hypertrophy. Although RAL corrected thymic hypertrophy, only E2 correct…

medicine.medical_specialtymedicine.drug_classOvariectomyImmunologyEstrogen receptorGenistein03 medical and health scienceschemistry.chemical_compoundEstrogen-related receptor alphaMice0302 clinical medicineImmune systemInternal medicinemedicineImmunology and AllergyAnimalsRaloxifeneEstrogen receptor betaCell ProliferationDNA PrimersPharmacologyBase SequenceEstradiolbusiness.industryReverse Transcriptase Polymerase Chain ReactionGenisteinMice Inbred C57BLEndocrinologychemistryReceptors EstrogenEstrogen030220 oncology & carcinogenesisImmune SystemRaloxifene HydrochlorideOvariectomized ratFemalebusiness030215 immunologymedicine.drugInternational journal of immunopathology and pharmacology
researchProduct

The Inhibitory Effects of Prednisone, 16-Methylen-Prednisolone, and Acth on Con-A Induced Lymphokines (Interferon-Y) as Measured by the Chemiluminesc…

1988

When lymphocytes are stimulated with mitogens or antigens they are enhanced via a cascade of lymphokines to produce interferon-y (IFN-y). IFN-y augments the H2O2 secretion of human monocytes which indirectly can be measured by chemiluminescence. We tested prednisone, 16-methylen-prednisolone and ACTH for their effect to inhibit the Con-A induced stimulation of the chemiluminescence-activity. All three hormones inhibited significantly the stimulation: prednisone up to 52.5% (concentration = 150 micrograms/ml, p = 0.000005), 16-methylen-prednisolone up to 22.5% (concentration = 2.5 micrograms/ml, p = 0.006) and ACTH up to 33% (concentration = 10 micrograms/ml, p = 0.0036).

medicine.medical_specialtymedicine.drug_classPrednisoloneImmunologyDose-Response Relationship ImmunologicStimulationAdrenocorticotropic hormoneToxicologyMonocytesInterferon-gammaAdrenocorticotropic HormoneInternal medicineConcanavalin AmedicineHumansImmunology and AllergyInterferon gammaPharmacologybiologybusiness.industryMonocyteLymphokineHydrogen PeroxideGeneral Medicinemedicine.anatomical_structureEndocrinologyConcanavalin ALuminescent Measurementsbiology.proteinPrednisolonePrednisoneCorticosteroidbusinessmedicine.drugImmunopharmacology and Immunotoxicology
researchProduct

OP0048 Outcomes in Systemic Lupus Erythematous (SLE) Patients Treated with Belimumab in Clinical Practice Settings: Results from the Observe Study in…

2014

Background Large-scale clinical trials have demonstrated clinical efficacy of belimumab in SLE patients. Objectives This study examined the clinical outcomes associated with belimumab in clinical practice settings in Germany. Methods OBSErve (GSK 117214) is a multi-center retrospective medical chart review study. Twenty-one rheumatologists from Germany treating >10 SLE-patients annually and with at least >5 yrs of practice experience were selected for data reporting. Adult SLE patients meeting the ACR classification criteria who received belimumab (10mg/kg) as part of usual care were identified for chart abstraction. Index date was the date of belimumab initiation. The primary outcome measu…

medicine.medical_specialtymedicine.drug_classbusiness.industryMedical recordImmunologymedicine.diseaseRashBelimumabGeneral Biochemistry Genetics and Molecular BiologyDiscontinuationClinical trialRheumatologyHeart failureInternal medicinemedicinePhysical therapyImmunology and AllergyCorticosteroidmedicine.symptomAdverse effectbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

2020

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported&mdash

medicine.medical_specialtymedicine.drug_classlcsh:MedicineTyrosine-kinase inhibitorArticle03 medical and health sciences0302 clinical medicinechronic myeloid leukemiahemic and lymphatic diseasesInternal medicineRetrospective analysisMedicineIn patientchronic myeloid leukemia; treatment-free remission; molecular monitoringtreatment-free remissionbusiness.industrylcsh:RMyeloid leukemiaGeneral MedicineDiscontinuationmolecular monitoringchronic myeloid leukemia; molecular monitoring; treatment-free remission030220 oncology & carcinogenesisMajor Molecular ResponseCohortbusinessOff Treatment030215 immunologyJournal of clinical medicine
researchProduct

Antithrombotic treatment and outcomes of splanchnic vein thrombosis in an international prospective registry: Results of 2-year follow-up

2014

Abstract Background: Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT). We aimed to assess incidence rates of bleeding, recurrence, and mortality in a large prospective cohort of SVT patients after a 2-year follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Information was gathered on baseline characteristics, risk factors and therapeutic strategies. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis, and mortality) during follow-up were collected and reviewed by a Central Adjudication Committee. Major bleeding was de…

medicine.medical_specialtymedicine.drug_classliver cirrhosisImmunologyanticoagulant agentBiochemistrymaleInternal medicinedeathMedicinefollow upartery thrombosishumanRisk factorProspective cohort studythrombosisriskregisteranticoagulant therapybusiness.industryhematologyIncidence (epidemiology)pathogenesisAnticoagulantCell Biologymedicine.diseasebleedingThrombosismortalitySurgeryVenous thrombosissocietySplanchnic vein thrombosisvein thrombosisrisk factorsolidincidenceantivitamin KpatientbusinessAmericanFibrinolytic agentneoplasmhospitalizationportal vein
researchProduct